COO operates in the ophthalmic goods sector, primarily focusing on medical devices.
It is a specialized player dedicated to innovative vision care solutions and treatments.
Updated: February 27, 2026, 16:00 EST
Technical Analysis COO has demonstrated strong short-term momentum, significantly outperforming the market with an 18.14% gain over three months. While trading in the upper third of its 52-week range, it remains 9% below its peak, suggesting potential for further appreciation if the trend continues. The near-market beta indicates these returns are being achieved with typical volatility levels.
Fundamentals Revenue stability at around $1.07 billion contrasts with concerning profitability trends, as net margins contracted from 9.3% to 7.9% amid gross profit declines. The company maintains a healthy low-debt structure but shows operational inefficiency through a very low 1.0% ROE and a cash conversion cycle of 176 days, indicating potential inventory management issues.
Valuation COO appears significantly overvalued with a trailing P/E of 70.83 and forward P/E of 40.93, far exceeding reasonable earnings multiples. The exceptionally high EV/EBITDA of 76.78 and negative PEG ratio highlight a substantial premium not supported by current growth metrics or profitability.
Risk While COO's beta near 1.0 suggests market-average volatility, its 30% maximum drawdown last year indicates notable downside potential during market stress. The absence of short interest reduces near-term bearish pressure but doesn't mitigate operational or valuation risks.
COO's strong recent momentum is overshadowed by deteriorating profitability, operational inefficiencies, and extreme valuation multiples. While the technical picture shows room for growth, the fundamentals do not justify the current premium price. Investors should wait for evidence of improved operational efficiency or a more reasonable valuation before considering a position. The current risk-reward profile appears unfavorable despite the positive price action.
Based on the provided analysis, here is a 12-month outlook for The Cooper Companies (COO):
Outlook: The outlook for COO is cautious over the next 12 months, presenting a challenging risk-reward profile. While strong recent momentum could continue in the near term, the extreme valuation and operational headwinds create significant vulnerability.
1. Key Catalysts: Positive catalysts would be a meaningful improvement in net margins and a reduction in the cash conversion cycle, demonstrating better operational efficiency. A sustained rebound in the broader healthcare sector could also provide tailwinds. 2. Potential Risks: The primary risk is a potential de-rating of its lofty valuation multiples (P/E ~71) if profitability fails to accelerate. Further margin compression or signs of slowing revenue growth would likely lead to significant price depreciation. 3. Target Price: Given the analyst target is listed as "None" and the stock trades 9% below its 52-week high, a re-test of the $92-$95 range is possible if momentum persists. However, the weak fundamentals suggest a sustainable move above $100 is unlikely, with downside risk toward the $70s if the valuation contracts. A Hold rating is appropriate.
Most Wall Street analysts are optimistic about The Cooper Companies, Inc.'s 12-month outlook, with consensus target around $83.67, indicating expected upside potential.
Overall, COO has investment potential but also faces challenges. Here are key factors to weigh before investing.
COO has demonstrated strong momentum with significant outperformance versus the market over the past quarter.
The stock has delivered robust gains of 4.1% over one month and 18.14% over three months, substantially outperforming the broader market by over 12 percentage points during the latter period. This consistent positive momentum, combined with a beta near 1.0, indicates the stock is delivering strong returns with market-average volatility.
Currently trading at $84.01, COO sits approximately in the upper third of its 52-week range ($61.78 - $92.84), suggesting it is neither severely overbought nor oversold. However, the stock remains more than 9% below its yearly high, indicating there is still room for appreciation despite the recent strong advance and a significant maximum drawdown of nearly 30% over the past year.
| Period | COO Return | S&P 500 |
|---|---|---|
| 1m | +4.0% | -1.4% |
| 3m | +10.9% | +4.1% |
| 6m | +13.8% | +7.5% |
| 1y | -7.4% | +15.4% |
| ytd | +3.2% | +0.4% |
Revenue & Profitability: Revenue remained stable at approximately $1.07 billion in Q3 and Q4 of 2025, but profitability weakened. The net profit margin declined from 9.3% to 7.9% quarter-over-quarter, reflecting margin pressure as the gross profit ratio fell significantly from 65.3% to 56.4%. This suggests challenges in maintaining profitability despite steady top-line performance.
Financial Health: The company maintains a low debt profile with a conservative debt-to-equity ratio of 0.34 and a comfortable interest coverage ratio of 5.75. However, the cash flow to debt ratio is relatively weak at 0.09, indicating limited operating cash flow generation relative to outstanding debt obligations, which warrants monitoring.
Operational Efficiency: Operational efficiency metrics appear challenged, with a low return on equity of 1.0% and an asset turnover of just 0.086. The extended cash conversion cycle of 176 days, driven by high days of inventory outstanding (164 days), suggests inefficient working capital management and potential inventory obsolescence risks.
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
Try Now & Get Tesla Stock RewardBased on the available metrics, COO appears significantly overvalued. The trailing PE ratio of 70.83 and forward PE of 40.93 are extremely high, suggesting investors are paying a substantial premium for its current and near-future earnings. This overvaluation is further corroborated by an elevated EV/EBITDA of 76.78 and a negative PEG ratio, which indicates either negative earnings growth expectations or that the high PE is not justified by its growth rate.
A direct peer comparison cannot be performed due to the unavailability of industry average data. However, the valuation multiples stand out as exceptionally high on an absolute basis, particularly the PE and EV/EBITDA ratios. The negative PEG ratio is also a significant concern, as it signals a disconnect between the stock's price and its perceived growth trajectory.
Volatility Risk: COO exhibits market-like volatility with a Beta of 1.027, indicating its price moves are generally in line with the broader market. However, the stock carries significant volatility risk, as evidenced by a substantial one-year maximum drawdown of -29.82%, pointing to notable downside price swings.
Other Risks: The stock appears to have no short interest, which suggests a lack of prevalent bearish sentiment from traders. This factor, however, does not eliminate other potential risks, such as company-specific operational challenges or broader market liquidity conditions that could still impact the investment.
Bearish - while COO shows strong momentum and low debt, it appears overvalued with a high P/E ratio (~71) and faces profitability concerns due to declining margins and operational inefficiencies. This stock is likely unsuitable for value investors or those seeking stability, but may hold speculative appeal for momentum traders willing to accept high risk.
Based on the provided data, COO appears significantly overvalued. The trailing P/E of 70.83 and forward P/E of 40.93 are exceptionally high on an absolute basis and indicate a substantial premium for its earnings. This overvaluation is particularly striking given the negative PEG ratio of -3.34, which signals that its high price is not supported by expected earnings growth. The concerning fundamentals, including declining profit margins, a low return on equity of 1.0%, and operational inefficiencies, further undermine the justification for such elevated valuation multiples.
Based on the provided information, here are the key risks of holding COO, ordered by importance:
1. Business/Operational Risk: The company faces significant profitability and operational efficiency challenges, as evidenced by a sharp decline in gross and net profit margins, a very low asset turnover, and an excessively long cash conversion cycle of 176 days indicating potential inventory management issues. 2. Financial Risk: While the debt level is low, the weak cash flow to debt ratio of 0.09 indicates a limited ability to cover debt obligations from operating cash flows, which could constrain financial flexibility. 3. Market Risk: The stock carries substantial volatility risk, with a one-year maximum drawdown of -29.82%, meaning investors are exposed to significant potential downside price swings despite its market-average beta.
Based on the provided analysis, here is a forecast for The Cooper Companies (COO) through 2026.
Through 2026, COO faces a challenging outlook, with a base case target price range of $70-$85 and a bull case of $95-$105 contingent on a successful operational turnaround. The key growth drivers are improvement in net margins, a reduction in the inefficient 176-day cash conversion cycle, and a sustained rebound in the healthcare sector. These forecasts assume management can address operational inefficiencies without significant revenue disruption and that premium valuation multiples can be sustained. However, this forecast is highly uncertain given the stark disconnect between its extreme valuation (P/E ~71) and weakening profitability, creating significant vulnerability to a potential de-rating if execution falters.